Condensed Consolidated Statements of Loss - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Mar. 31, 2022 |
Mar. 31, 2021 |
|
| Operating expenses | ||
| Research and development, net of tax credits | $ 8,768 | $ 8,595 |
| General and administrative | 3,643 | 2,633 |
| Commercial | 1,636 | 1,366 |
| Loss from operations | (14,047) | (12,594) |
| Interest income, net | 40 | 80 |
| Net loss | $ (14,007) | $ (12,514) |
| Weighted average number of shares and pre-funded warrants outstanding, basic | 42,243,021 | 41,256,248 |
| Weighted average number of shares and pre-funded warrants outstanding, diluted | 42,243,021 | 41,256,248 |
| Net loss per share, basic | $ (0.33) | $ (0.30) |
| Net loss per share, diluted | $ (0.33) | $ (0.30) |
| X | ||||||||||
- Definition Expenses recognized in the period that are directly related to the commercial of products or services. No definition available.
|
| X | ||||||||||
- Definition Number of basic shares or units and pre-funded warrants, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time. No definition available.
|
| X | ||||||||||
- Definition Number of diluted shares or units and pre-funded warrants, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time. No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|